Hong Kong pharmaceutical IPO soared, the first half of the fundraising amount reached 15.60 billion Hong Kong dollars

On July 4th, according to the statistics disclosed by the Hong Kong Stock Exchange, as of June 30, a total of 10 biomedical companies successfully listed on the Hong Kong Stock Exchange in the first half of this year, compared with only 12 in the whole of last year. From the perspective of specific industry distribution, 6 belong to the pharmaceutical biological industry, and 4 belong to the medical equipment and service industry. The two ranked among the top two in the number of IPOs issued in Hong Kong in various industries of Wind in the first half of the year. Since the beginning of 2025, as many as 39 medical and health companies have been queuing up for listing on the Hong Kong Stock Exchange. According to Deloitte statistics, in Quarter 1 this year, the number of active applications for listing on the main board of Hong Kong reached 118, a significant increase year-on-year, of The surge in Hong Kong pharmaceutical IPOs is not only reflected in the number, but also in the total amount of funds raised. According to relevant information, the pharmaceutical and biological industry raised HK $15.60 billion in the first six months, which is the second highest industry in the current Hong Kong IPO fundraising scale, significantly higher than the average level of the past three years. Looking forward to the second half of 2025, the enthusiasm of companies going to Hong Kong for IPOs continues, with more than 40 biomedical companies queuing up for listing.